ABVC | tickerfilter.com

Fundamental analysis

46%

Profitability 35%

Dept financing 31%

Liquidity 28%

Performance 65%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-11.50%

1 Month

-32.43%

3 Months

-56.71%

6 Months

-67.53%

1 Year

-5.66%

2 Year

-27.01%

Key data

Stock price

$1.00

P/E Ratio

N/A

DAY RANGE

$0.97 - $1.07

EPS

-$0.39

52 WEEK RANGE

$0.73 - $5.48

52 WEEK CHANGE

-$5.66

MARKET CAP

0.000

YIELD

N/A

SHARES OUTSTANDING

0.000

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

04-29-2025

BETA

0.01

PUBLIC FLOAT

AVERAGE 10 VOLUME

$56,485

AVERAGE 30 VOLUME

$58,274

Company detail

CEO: Howard Doong
Region: US
Website: abvcpharma.com
Employees: 30
IPO year: 2019

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

ABVC BioPharma, Inc. develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase I/II clinical trials a combination therapy for triple negative breast cancer. ABV-1504 has completed Phase II clinical trials for major depressive disorders. ABV1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage.

ABVC - ABVC BIOPHARMA, INC.